| Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation ML Maitland, J Wilkerson, S Karovic, B Zhao, J Flynn, M Zhou, P Hilden, ... Clinical Cancer Research 26 (24), 6464-6474, 2020 | 22 | 2020 |
| A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide H Leuva, K Sigel, M Zhou, J Wilkerson, DH Aggen, YHA Park, ... Seminars in Oncology 46 (4-5), 351-361, 2019 | 18 | 2019 |
| Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer KB Blagoev, R Iordanov, M Zhou, T Fojo, SE Bates Oncotarget 12 (1), 15, 2021 | 7 | 2021 |
| Gemcitabine plus nab‐paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans K Sigel, M Zhou, YHA Park, T Mutetwa, G Nadkarni, C Yeh, P Polak, ... Seminars in oncology 48 (1), 69-75, 2021 | 5 | 2021 |
| Influence of cancer on COVID-19 incidence, outcomes, and vaccine effectiveness: A prospective cohort study of US Veterans H Leuva, M Zhou, N Brau, ST Brown, P Mundi, TCM Rosenberg, C Luhrs, ... Seminars in Oncology 49 (5), 363-370, 2022 | 4 | 2022 |
| Distribution of cancer genes in human chromosomes B Laderian, M Zhou, T Fojo Seminars in Oncology 47 (6), 409-413, 2020 | 4 | 2020 |
| Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data C Yeh, M Zhou, K Sigel, G Jameson, R White, R Safyan, Y Saenger, ... The oncologist 28 (2), 139-148, 2023 | 2 | 2023 |
| A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals. C Yeh, M Zhou, N Bapodra, M Rivero, EJ Espinal Dominguez, M Moran, ... Journal of Clinical Oncology 40 (16_suppl), 1069-1069, 2022 | 1 | 2022 |
| Assessment of PSA responses and changes in the rate of tumor growth (g-rate) with immune checkpoint inhibitors in US Veterans with prostate cancer H Leuva, G Moran, N Jammaleddine, M Maseeha, M Zhou, Y Im, ... Seminars in Oncology, 2024 | | 2024 |
| Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials C Yeh, M Zhou, N Bapodra, D Hershman, E Espinal, M Moran, M Rivero, ... Breast Cancer Research and Treatment 204 (1), 39-47, 2024 | | 2024 |
| Dynamic Changes in Lymph Node Size and Skin Scoring Predict Response to Treatment in CTCL: An Interim Analysis LM Fahmy, HR Yang, M Zhou, V Beylergil, CM Schreidah, Z Bilgrami, ... Blood 142, 4443, 2023 | | 2023 |
| 1328P Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual … M LaRose, M Zhou, S Lu, H Wei, SE Bates, L Schwartz, AT Fojo Annals of Oncology 34, S766-S767, 2023 | | 2023 |
| LYMPH NODE AND SKIN SCORING GROWTH KINETICS PREDICT OUTCOMES IN CUTANEOUS T‐CELL LYMPHOMA: AN INTERIM ANALYSIS LM Fahmy, HR Yang, M Zhou, V Beylergil, CM Schreidah, BD Kwinta, ... Hematological Oncology 41, 772-772, 2023 | | 2023 |
| Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor … H Leuva, M Zhou, R Stamatov, BA Teply, TCM Rosenberg, CA Luhrs, ... Journal of Clinical Oncology 41 (16_suppl), 5076-5076, 2023 | | 2023 |
| An analysis to inform the timing of docetaxel use leveraging data from the United States Veterans Administration on patients with metastatic castration-sensitive prostate … M Zhou, H Leuva, R Stamatov, PS Mundi, YHA Park, SE Bates, I Faiena, ... Journal of Clinical Oncology 41 (16_suppl), 5085-5085, 2023 | | 2023 |
| A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example. AT Fojo, M Zhou, M LaRose, SE Bates, LH Schwartz Journal of Clinical Oncology 41 (16_suppl), 2609-2609, 2023 | | 2023 |
| Using tumor growth rate to inform treatment efficacy in pancreatic adenocarcinoma: From the metastatic to the neoadjuvant setting. M LaRose, C Yeh, M Zhou, KM Sigel, GS Jameson, RA White, RA Safyan, ... Journal of Clinical Oncology 41 (4_suppl), 726-726, 2023 | | 2023 |
| Estimates of the rate of growth of lymph nodes measured volumetrically predicts survival in cutaneous T-cell lymphoma (CTCL) LM Fahmy, HR Yang, M Zhou, V Beylergil, CM Schreidah, LH Schwartz, ... European Journal of Cancer 173, S36, 2022 | | 2022 |
| The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Administration … H Leuva, M Zhou, J Wilkerson, K Sigel, TC Hsu, DH Aggen, E Langhoff, ... Journal of Clinical Oncology 37 (15_suppl), 5074-5074, 2019 | | 2019 |
